Transamerica Financial Advisors Inc. Purchases 3,274 Shares of GSK plc (NYSE:GSK)

Transamerica Financial Advisors Inc. boosted its position in shares of GSK plc (NYSE:GSK) by 1,488.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,494 shares of the pharmaceutical company’s stock after buying an additional 3,274 shares during the period. Transamerica Financial Advisors Inc.’s holdings in GSK were worth $143,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GSK. Eastern Bank purchased a new stake in GSK during the third quarter valued at approximately $26,000. Concord Wealth Partners raised its position in GSK by 231.8% during the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after purchasing an additional 547 shares during the period. Ashton Thomas Private Wealth LLC purchased a new stake in GSK during the second quarter valued at approximately $37,000. Fortitude Family Office LLC purchased a new stake in GSK during the third quarter valued at approximately $42,000. Finally, PrairieView Partners LLC purchased a new stake in GSK during the second quarter valued at approximately $47,000. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on GSK. Argus upgraded GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Deutsche Bank Aktiengesellschaft downgraded GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group downgraded GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. Barclays upgraded GSK to a “hold” rating in a report on Tuesday, August 27th. Finally, Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Seven analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 0.9 %

GSK opened at $34.32 on Thursday. The stock’s fifty day moving average is $37.56 and its two-hundred day moving average is $40.13. The company has a market capitalization of $71.13 billion, a P/E ratio of 22.29, a PEG ratio of 1.31 and a beta of 0.66. GSK plc has a 52 week low of $32.83 and a 52 week high of $45.92. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.3928 per share. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a yield of 4.58%. The ex-dividend date is Friday, November 15th. GSK’s dividend payout ratio (DPR) is presently 99.35%.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk purchased 2,791,930 shares of GSK stock in a transaction dated Friday, September 27th. The stock was purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the transaction, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 10.00% of the stock is currently owned by company insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.